CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 357 enrolled
Drug / intervention
Loteprednol and tobramycin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01028027
NCT01028027Phase 3Completed
CompareCT.gov

A Clinical Safety and Efficacy Evaluation of Zylet® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis

Bausch & Lomb Incorporated·interventional·Posted Dec 9, 2009·Updated Feb 28, 2012

In Brief

A Phase 3 clinical trial evaluating Loteprednol and tobramycin and Tobramycin and dexamethasone for Conjunctivitis and 2 related conditions. Completed, enrolled 357 participants across 1 site.

Detailed Summary

This study is to evaluate the safety and efficacy of loteprednol etabonate \[LE\] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Keratitis, Blepharitis
CountriesSingapore
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 9, 2009
Enrollment StartOct 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.6 years ago

Interventions

Loteprednol and tobramycindrug

Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.

Tobramycin and dexamethasonedrug

Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.